Group 1 - The third meeting of the supervisory board of Shanghai Yinos Biotech Co., Ltd. was held on August 27, 2025, with all three supervisors present, and the meeting was conducted in accordance with legal and regulatory requirements [1] - The supervisory board approved the proposal regarding the company's 2025 semi-annual report, affirming that the report accurately reflects the company's operational management and financial status for the first half of 2025 [1][2] - The supervisory board also approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with relevant regulations and that there were no misrepresentations or omissions [2][4] Group 2 - The supervisory board agreed to the proposal for the reappointment of the accounting firm, which will be submitted for approval at the company's third extraordinary general meeting of shareholders in 2025 [3] - The board approved the use of temporarily idle raised funds for cash management, aiming to enhance the efficiency of fund utilization and increase returns on cash assets, while ensuring the protection of shareholder interests [3][4]
益诺思: 第三届监事会第十二次会议决议公告